Atossa Genetics, Inc.
(NASDAQ : ATOS)

( )
ATOS PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Medical Specialties
symbolcompany%chnglast%shortavg$volume
TMOThermo Fisher Scientific Inc.
0.21%284.231.0%$453.34m
MDTMedtronic PLC
-0.02%107.560.6%$434.49m
ABTAbbott Laboratories
0.23%79.810.8%$318.41m
BSXBoston Scientific Corporation
-0.71%37.961.1%$289.96m
ISRGIntuitive Surgical, Inc.
0.16%518.882.4%$288.76m
EWEdwards Lifesciences Corporation
-0.24%226.561.2%$255.27m
SYKStryker Corporation
-0.57%212.601.3%$237.39m
BDXBecton, Dickinson and Company
-0.91%250.551.1%$233.41m
ALGNAlign Technology, Inc.
2.49%205.156.3%$232.09m
BAXBaxter International Inc.
-1.00%87.151.7%$226.28m
PODDInsulet Corporation
-0.74%152.256.9%$160.20m
ZBHZimmer Biomet Holdings, Inc.
-0.87%135.251.7%$139.05m
WATWaters Corporation
0.12%213.884.0%$124.72m
ABMDABIOMED, Inc.
4.05%176.513.3%$113.51m
PENPenumbra, Inc.
-0.78%144.808.7%$107.81m

Company Profile

Atossa Genetics, Inc. operates as a clinical-stage pharmaceutical company, which focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. It offers ForeCYTE and ArgusCYTE diagnostic tests. The ForeCYTE Breast Health Test provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 65. The ArgusCYTE Breast Health Test offers information to help inform breast cancer treatment options and to help monitor potential recurrence. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.